Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05687916




Registration number
NCT05687916
Ethics application status
Date submitted
9/01/2023
Date registered
18/01/2023
Date last updated
17/05/2024

Titles & IDs
Public title
A Study of TAK-861 in Participants With Narcolepsy Type 2
Scientific title
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2)
Secondary ID [1] 0 0
2022-002966-34
Secondary ID [2] 0 0
TAK-861-2002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Narcolepsy Type 2 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TAK-861
Treatment: Drugs - Placebo

Experimental: TAK-861 Dose 1 - TAK-861 dose 1, orally for 8 weeks.

Experimental: TAK-861 Dose 2 - TAK-861 dose 2, orally for 8 weeks.

Placebo Comparator: Placebo - TAK-861 matching placebo tablets, orally for 8 weeks.


Treatment: Drugs: TAK-861
TAK-861 tablets.

Treatment: Drugs: Placebo
TAK-861 placebo matching tablets.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline to Week 8 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT)
Timepoint [1] 0 0
Baseline, Week 8
Secondary outcome [1] 0 0
Change from Baseline to Week 8 in Epworth Sleepiness Scale (ESS) Total Score
Timepoint [1] 0 0
Baseline, Week 8
Secondary outcome [2] 0 0
Percentage of Participants who Experience at Least one Treatment Emergent Adverse Event (TEAE)
Timepoint [2] 0 0
From baseline up to approximately 12 weeks

Eligibility
Key inclusion criteria
- The participant is aged 18 to 70 years, inclusive, at the time of signing the informed
consent form (ICF).

Note: In Japan, participants aged 16 to 70 years, inclusive, may be included.

- The participant has an International Classification of Sleep Disorders, 3rd edition
(ICSD-3) diagnosis of NT2 by preceding polysomnography (PSG)/ multiple sleep latency test
(MSLT), performed within the past 5 years.

Note: If there is a potential participant with NT2 for whom a diagnostic nocturnal
polysomnography (nPSG)/MSLT was performed more than 5 years ago or is not available, the
site may repeat the diagnostic PSG/MSLT.
Minimum age
16 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- The participant has a current medical disorder, other than narcolepsy without
cataplexy, associated with EDS.

- The participant has history of epilepsy, seizure, or convulsion, or has a family
history of inherited disorders associated with seizure (except for a single febrile
seizure in childhood).

- The participant has one or more of the following psychiatric disorders:

1. Any current unstable psychiatric disorder.

2. Current or history of manic or hypomanic episode, schizophrenia or any other
psychotic disorder, including schizoaffective disorder, major depression with
psychotic features, bipolar depression with psychotic features, obsessive
compulsive disorder, mental retardation, organic mental disorders, or mental
disorders due to a general medical condition as defined in the Diagnostic and
Statistical Manual of Mental Disorders, 5th Edition (DSM-5).

3. Current diagnosis or history of substance use disorder as defined in the DSM-5.
Note: If the history of substance use disorder is more than 12 months before
baseline, the participant may be allowed to enroll in the study after
consultation with the sponsor or designee. (Participant must also have negative
urine drug screen at the screening and Day -2 visit.)

4. Current active major depressive episode (MDE) or who have had an active MDE in
the past 6 months.

- The participant has a history of cerebral ischemia, transient ischemic attack (<5
years ago), intracranial aneurysm, or arteriovenous malformation.

- The participant had major surgery or donated or lost 1 unit of blood (approximately
500 mL) within 4 weeks before the screening visit.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/12/2023
Sample size
Target
Accrual to date
Final
71
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Woolcock Institute of Medical Research - Glebe
Recruitment postcode(s) [1] 0 0
2037 - Glebe
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
South Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Virginia
Country [15] 0 0
Finland
State/province [15] 0 0
Uusimaa
Country [16] 0 0
France
State/province [16] 0 0
Herault
Country [17] 0 0
France
State/province [17] 0 0
Isere
Country [18] 0 0
France
State/province [18] 0 0
Paris
Country [19] 0 0
Germany
State/province [19] 0 0
Mecklenburg-Vorpommern
Country [20] 0 0
Germany
State/province [20] 0 0
Berlin
Country [21] 0 0
Italy
State/province [21] 0 0
Lazio
Country [22] 0 0
Italy
State/province [22] 0 0
Molise
Country [23] 0 0
Italy
State/province [23] 0 0
Bellaria
Country [24] 0 0
Japan
State/province [24] 0 0
Akita
Country [25] 0 0
Japan
State/province [25] 0 0
Ehime
Country [26] 0 0
Japan
State/province [26] 0 0
Hukuoka
Country [27] 0 0
Japan
State/province [27] 0 0
Kumamoto
Country [28] 0 0
Japan
State/province [28] 0 0
Osaka
Country [29] 0 0
Japan
State/province [29] 0 0
Tokyo
Country [30] 0 0
Japan
State/province [30] 0 0
Nagakute
Country [31] 0 0
Japan
State/province [31] 0 0
Yokohama
Country [32] 0 0
Netherlands
State/province [32] 0 0
Noord-Brabant
Country [33] 0 0
Netherlands
State/province [33] 0 0
Noord-Holland
Country [34] 0 0
Norway
State/province [34] 0 0
Oslo
Country [35] 0 0
Spain
State/province [35] 0 0
Alava
Country [36] 0 0
Spain
State/province [36] 0 0
Castellon
Country [37] 0 0
Spain
State/province [37] 0 0
Valencia
Country [38] 0 0
Spain
State/province [38] 0 0
Barcelona
Country [39] 0 0
Spain
State/province [39] 0 0
Madrid
Country [40] 0 0
Sweden
State/province [40] 0 0
Vastra Gotalands Lan
Country [41] 0 0
Switzerland
State/province [41] 0 0
Aargau (de)
Country [42] 0 0
Switzerland
State/province [42] 0 0
Ticino (it)
Country [43] 0 0
Switzerland
State/province [43] 0 0
Bern

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including
excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of
Wakefulness Test (MWT).

The study will enroll approximately 60 participants and they will be randomly assigned to 3
groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the
participants will receive the treatment for 8 weeks. Participants will be asked to complete
some questionnaires during the study. This trial will be conducted in North America, Europe,
and Asia Pacific.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05687916
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries